Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology.

Brugières L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, Pondarré C, Leverger G, Devalck C, Rodary C, Delsol G, Hartmann O.

Blood. 1998 Nov 15;92(10):3591-8.

2.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
3.

[Treatment of primary mediastinal large B-cell lymphomas].

Schneider T, Tóth E, Molnár Z, Várady E, Deák B, Horváth A, Horváth GI, Eid H, Schneider K, Lovey J, Keresztes S, Esik O, Lengyel Z, Rosta A.

Orv Hetil. 2004 Dec 12;145(50):2531-7. Hungarian.

PMID:
15662753
4.

Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases.

Rubie H, Gladieff L, Robert A, Gaubert I, Huguet F, Rochaix P, Pein F, Michel G, Hoerni B, Sommelet D, et al.

Med Pediatr Oncol. 1994;22(3):155-61.

PMID:
8272005
5.

Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL).

Massimino M, Spreafico F, Luksch R, Giardini R.

Med Pediatr Oncol. 2001 Aug;37(2):97-102.

PMID:
11496346
6.

Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.

Chen YC, Ho CL, Kao WY, Hwang JM, Sheu LF, Chao TY.

Ann Hematol. 2001 Nov;80(11):647-52.

PMID:
11757723
7.

Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.

Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, Thiel E, Wilmanns W, Aydemir U, Bierwolf S, Griesser H, Tiemann M, Lennert K.

Blood. 1997 Apr 1;89(7):2291-7.

8.

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF; Dutch-Belgian Hemato-Oncology Cooperative Group..

J Clin Oncol. 2005 Jun 1;23(16):3793-801. Epub 2005 Apr 4.

PMID:
15809447
9.

[Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].

Vinogradova IuE, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Gorgidze LA, Ryzhikova NA, Valiev TT, Giliazitdinova EA, Dzhulakian UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremenetskaia AM, Kravchenko SK, Vorob'ev AI.

Ter Arkh. 2008;80(7):33-7. Russian.

PMID:
18763592
10.

Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group.

Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K, Schrappe M, Zimmermann M, Niemeyer C, Parwaresch R, Riehm H, Reiter A; NHL Berlin-Frankfurt-Münster Group..

J Clin Oncol. 2003 May 1;21(9):1782-9.

PMID:
12721255
11.
12.

Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.

Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.

Haematologica. 1998 Sep;83(9):800-11.

14.

Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.

Atra A, Imeson JD, Hobson R, Gerrard M, Hann IM, Eden OB, Carter RL, Pinkerton CR.

Br J Cancer. 2000 Apr;82(8):1396-402.

15.

Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology.

Brugières L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, Schmitt C, Landmann J, Patte C, Terrier-Lacombe MJ, Delsol G, Hartmann O.

Ann Oncol. 2000 Jan;11(1):53-8.

PMID:
10690387
16.

Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.

Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E.

Bone Marrow Transplant. 2002 Mar;29(6):473-7.

17.

Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults.

Fanin R, Silvestri F, Geromin A, Cerno M, Infanti L, Zaja F, Barillari G, Savignano C, Rinaldi C, Damiani D, Baccarani M.

Leuk Lymphoma. 1997 Jan;24(3-4):369-77.

PMID:
9156668
19.

Anaplastic large cell lymphoma, ALK-positive.

Ferreri AJ, Govi S, Pileri SA, Savage KJ.

Crit Rev Oncol Hematol. 2012 Aug;83(2):293-302. doi: 10.1016/j.critrevonc.2012.02.005. Epub 2012 Mar 21. Review.

PMID:
22440390
20.

Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.

Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E.

Cancer. 2000 May 1;88(9):2142-8.

PMID:
10813727

Supplemental Content

Support Center